NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $4.38 -0.19 (-4.16%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.33 -0.05 (-1.23%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$4.30▼$4.6650-Day Range$4.13▼$5.4952-Week Range$3.61▼$11.09Volume87,285 shsAverage Volume210,494 shsMarket Capitalization$48.57 millionP/E RatioN/ADividend YieldN/APrice Target$47.00Consensus RatingBuy Company Overview Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Read More Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 148th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.33% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 16.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted13.33% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 16.92%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News Sentiment-0.44 News SentimentPrecision BioSciences has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Precision BioSciences this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold 807.12% more of their company's stock than they have bought. Specifically, they have bought $6,963.00 in company stock and sold $63,163.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Stock News HeadlinesPrecision BioSciences, Inc. (NASDAQ:DTIL) CFO Sells $63,163.02 in StockJuly 9, 2025 | insidertrades.comDTIL Revenue Drops 99%August 7 at 12:08 PM | fool.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7 at 7:01 AM | businesswire.comPrecision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis BAugust 6 at 7:01 AM | businesswire.comPrecision BioSciences (DTIL) Expected to Announce Quarterly Earnings on ThursdayAugust 6 at 2:55 AM | americanbankingnews.comPrecision BioSciences to Report Second Quarter 2025 Results on August 7, 2025August 4, 2025 | businesswire.comPrecision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyJuly 23, 2025 | businesswire.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $3.81 on January 1st, 2025. Since then, DTIL shares have increased by 15.0% and is now trading at $4.38. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) announced its earnings results on Thursday, August, 7th. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $2.04. The business earned $0.02 million during the quarter, compared to analysts' expectations of $6.27 million. Precision BioSciences had a negative net margin of 6,205.79% and a negative trailing twelve-month return on equity of 158.77%. When did Precision BioSciences' stock split? Precision BioSciences's stock reverse split on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' top institutional investors include Geode Capital Management LLC (0.70%). Insiders that own company stock include J Jefferson Smith, John Alexander Kelly, Melinda Brown, Geno J Germano, Dario Scimeca and Alan List. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Precision BioSciences$47.00 High Price Target$60.00 Low Price Target$34.00 Potential Upside/Downside+973.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$7.17 million Net Margins-6,205.79% Pretax Margin-42.99% Return on Equity-158.77% Return on Assets-65.42% Debt Debt-to-Equity Ratio0.45 Current Ratio6.62 Quick Ratio6.62 Sales & Book Value Annual Sales$68.70 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value$6.87 per share Price / Book0.64Miscellaneous Outstanding Shares11,090,000Free Float10,589,000Market Cap$48.57 million OptionableNo Data Beta1.52 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DTIL) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.